Ignite Creation Date:
2024-05-05 @ 5:00 PM
Last Modification Date:
2024-10-26 @ 9:26 AM
Study NCT ID:
NCT00361738
Status:
COMPLETED
Last Update Posted:
2009-02-09
First Post:
2006-08-07
Brief Title:
Dose-Ranging Study Evaluating AVE2268 in Patients With Type 2 Diabetes Not Adequately Controlled by a Metformin Treatment
Sponsor:
Sanofi
Organization:
Sanofi
Study Overview
Official Title:
A Randomized Double-Blind Parallel-Group Placebo-Controlled Dose-Response Multicentre Multinational Study Evaluating the Efficacy and Safety of AVE2268 Administered Either Twice Daily Breakfast and Lunch at a Dose of 300 600 and 1200 mg or Once Daily Breakfast at a Dose of 1200 mg in Patients With Type 2 Diabetes Treated With Metformin and Not Adequately Controlled
Status:
COMPLETED
Status Verified Date:
2009-02
Last Known Status:
None
Delayed Posting:
No
If Stopped, Why?:
Not Stopped
Has Expanded Access:
False
If Expanded Access, NCT#:
N/A
Has Expanded Access, NCT# Status:
N/A
Acronym:
None
Brief Summary:
Dose-ranging study of AVE2268 in the management of patients with type 2 diabetes mellitus also receiving metformin
Its main objectives will be to assess the effects of several doses of AVE2268 on Mean Plasma Glucose Its secondary objectives will be to assess the effects of AVE2268 on plasma glucose fasting and post-prandial and also the safety and tolerability of AVE2268
Its main objectives will be to assess the effects of several doses of AVE2268 on Mean Plasma Glucose Its secondary objectives will be to assess the effects of AVE2268 on plasma glucose fasting and post-prandial and also the safety and tolerability of AVE2268
Detailed Description:
None
Study Oversight
Has Oversight DMC:
None
Is a FDA Regulated Drug?:
None
Is a FDA Regulated Device?:
None
Is an Unapproved Device?:
None
Is a PPSD?:
None
Is a US Export?:
None
Is an FDA AA801 Violation?:
None
Secondary IDs
| Secondary ID | Type | Domain | Link |
|---|---|---|---|
| EUDRACT 2006-001843-74 | None | None | None |